ストックスクリーナーアプリを入手
0.2057
4.10%
0.0081
アフターアワーズ：
.20
-0.0057
-2.77%
前日終値:
$0.1976
開ける：
$0.204
24時間の取引高:
1.10M
Relative Volume:
0.67
時価総額：
$13.46M
収益：
$1.47M
当期純損益:
$-97.61M
株価収益率:
-0.1381
EPS:
-1.49
ネットキャッシュフロー:
$-80.90M
1週間 パフォーマンス:
-1.20%
1か月 パフォーマンス:
+6.86%
6か月 パフォーマンス:
-38.58%
1年 パフォーマンス:
-95.89%
1日の値動き範囲:
$0.1977
$0.2154
1週間の範囲:
$0.1943
$0.2154
52週間の値動き範囲:
$0.1625
$6.79
Lyra Therapeutics Inc Stock (LYRA) Company Profile
LYRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LYRA
Lyra Therapeutics Inc
|
0.2057 | 13.46M | 1.47M | -97.61M | -80.90M | -1.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lyra Therapeutics Inc Stock (LYRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-07 | ダウングレード | BofA Securities | Buy → Underperform |
| 2024-05-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-05-07 | ダウングレード | Jefferies | Buy → Hold |
| 2024-05-06 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-06 | 再開されました | BTIG Research | Buy |
| 2023-08-31 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-05-26 | 開始されました | BTIG Research | Buy |
| 2020-05-26 | 開始されました | BofA/Merrill | Buy |
| 2020-05-26 | 開始されました | Jefferies | Buy |
| 2020-05-26 | 開始されました | William Blair | Outperform |
すべてを表示
Lyra Therapeutics Inc (LYRA) 最新ニュース
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
Watch this stock’s price performance: Lyra Therapeutics Inc (NASDAQ:LYRA) - US Post News
Lyra Therapeutics Inc (LYRA) receives a Hold rating from Jefferies - Knox Daily
Examining the Potential Price Growth of Oshkosh Corp (OSK) - Knox Daily
Neuronetics Inc [STIM] Stock sold by Insider Furlong Stephen for $1122.0 - Knox Daily
BrightSpire Capital Inc [BRSP] Insider Activity: An Update for Investors - Knox Daily
LYRA’s 2023 Market Dance: Down -5.96% – Time to Invest? - The InvestChronicle
Lyra Therapeutics Inc (LYRA) Shares Rise Despite Market Challenges - The News Heater
Kailera Therapeutics Launches with $400 Million Series A Financing to Advance Portfolio of Next-Generation Therapies for Obesity and Related Conditions - Bain Capital
Deeper Dive: Understanding Immunome Inc (IMNM) Through its Various Ratios - The Dwinnex
LYRA News Today | Why did Lyra Therapeutics stock go up today? - MarketBeat
Selling Your Galaxy Payroll Group Ltd (GLXG) Stock? Here’s What You Need To Know - Stocks Register
New Outlook On ReNew Energy Global plc - Stocks Register
Open Lending Corp’s (LPRO) Stock Is Harder To Predict Than You Think - Stocks Register
There Is A Lot Of Upside Potential For Helius Medical Technologies Inc(NASDAQ: HSDT) - Stocks Register
New Outlook On Vestis Corp - Stocks Register
Data-Based Insights About MINISO Group Holding Ltd ADR (MNSO) - Stocks Register
Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know - MSN
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics - openPR
Revance Therapeutics jumps after Teoxane offers $3.60 a share - MSN
Cidara Therapeutics Announces Leadership Changes and Appointments - MSN
Are Investors Keen On Selling Holdings In Phoenix Motor Inc (NASDAQ: PEV)? - Stocks Register
State Street Corp Takes Position in Lotus Technology Inc. (NASDAQ:LOT) - Defense World
State Street Corp Has $126,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Edible Garden AG Inc (NASDAQ: EDBL): A Stock Worth Watching - Stocks Register
Fierce Biotech Layoff Tracker 2024: Vincerx reduces workforce; Novartis lays off 330 staffers - Fierce Biotech
Lyra Therapeutics reshuffles board, adjusts director classes - Investing.com
Lyra Therapeutics reshuffles board, adjusts director classes By Investing.com - Investing.com UK
Lyra Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Lyra Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lyra Therapeutics Inc’s (NASDAQ: LYRA) Stock Forecast: Increase To $0.5 In A Year - Stocks Register
Chronic Rhinosinusitis Without Nasal Polyps Therapeutics Market Size was ~USD 3,930 Million in the 7MM in 2023, estimated DelveInsight - Barchart
Incendia Therapeutics Names Healthcare Veteran Brad Smith as CFO, Brings $1B Financing Track Record - StockTitan
LYRA (Lyra Therapeutics) GF Score : 43/100 (As of Nov. 29, 2024) - GuruFocus.com
Analysts Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Price Target at $4.50 - Defense World
William Blair Has Positive Forecast for LYRA FY2024 Earnings - Defense World
HC Wainwright Expects Higher Earnings for Lyra Therapeutics - Defense World
Lyra Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Lyra Therapeutics stock plunges to 52-week low of $0.21 By Investing.com - Investing.com South Africa
Lyra Therapeutics stock plunges to 52-week low of $0.21 - Investing.com India
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates - MSN
Lyra Therapeutics Inc (LYRA) Q3 2024 Earnings: Net Loss of $11.9M, Misses EPS and Revenue Estimates - GuruFocus.com
Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Reports Strong Safety Data, Cuts Q3 Losses by 24% as LYR-210 Advances | LYRA Stock News - StockTitan
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) PT at $4.50 - Defense World
Chronic Rhinosinusitis Market: Driving Rapid Growth with Top - openPR
Lyra Therapeutics Inc (NASDAQ: LYRA) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatment By Investing.com - Investing.com Canada
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - The Manila Times
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Lyra Therapeutics Inc (LYRA) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):